Tumor Necrosis Factors
Research News and Information

Monday, November 23, 2009

Active-site determinants of substrate recognition by the metalloproteinases TACE and ADAM10.

21 Oct 2009 The metalloproteinases TACE [tumour necrosis factor alpha-converting enzyme; also known as ADAM17 (a disintegrin and metalloproteinase 17)] and ADAM10 are the primary enzymes responsible for catalysing release of membrane-anchored proteins from the ... Read more...

Cerebral microvascular IL15 is a novel mediator of TNF action.

29 Aug 2009 The blood-brain barrier is a gatekeeper and modulatory interface for the CNS. Cerebral endothelial cells are the major component of the blood-brain barrier, and they modify inflammatory signals from the circulation to the CNS by production and ... Read more...

Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts.

30 Jul 2009 We have recently shown that TNF-related weak inducer of apoptosis (TWEAK) is a mediator of inflammatory bone remodeling. The aim of this study was to investigate the role of TWEAK in modulating human osteoblast activity, and how TWEAK and TNFalpha ... Read more...

Latest indexed articles for 'Tumor Necrosis Factors'

These are the very latest articles for this heading:

• Active-site determinants of substrate recognition by the metalloproteinases TACE and ADAM10. 21 Oct 2009
• Golimumab. 30 Aug 2009
• Rheumatoid arthritis market. 30 Aug 2009
• Cerebral microvascular IL15 is a novel mediator of TNF action. 29 Aug 2009
• Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. 30 Jul 2009
• Enhancement of T-cell-mediated anti-tumour immunity via the ectopically expressed glucocorticoid-induced tumour necrosis factor receptor-related receptor ligand (GITRL) on tumours. 30 Jul 2009
• Simvastatin reduces endotoxin-induced nuclear factor kappaB activation and mortality in guinea pigs despite lowering circulating low-density lipoprotein cholesterol. 30 Jul 2009
• OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity. 30 Jul 2009
• Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiation. 28 Jul 2009
• Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis. 15 Jul 2009
• Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. 11 Jul 2009
• Is resveratrol the magic bullet for pulmonary hypertension? 11 Jul 2009
• Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand. 11 Jul 2009
• Improving TNF as a cancer therapeutic: tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects. 29 Jun 2009
• Regression of established AB1 murine mesothelioma induced by peritumoral injections of CpG oligodeoxynucleotide either alone or in combination with poly(I:C) and CD40 ligand plasmid DNA. 29 Jun 2009
• Elevated circulating TWEAK levels in systemic sclerosis: association with lower frequency of pulmonary fibrosis. 14 Jun 2009
• IKKbeta-mediated nuclear factor-kappaB activation attenuates smac mimetic-induced apoptosis in cancer cells. 7 Jun 2009
• T cells dampen innate immune responses through inhibition of NLRP1 and NLRP3 inflammasomes. Jun 2009
• Considering TWEAK as a target for therapy in renal and vascular injury. 28 May 2009
• Platelet-activating factor induces the processing of nuclear factor-kappaB p105 into p50, which mediates acute bowel injury in mice. 19 May 2009

See a longer list of these articles.

Technical information about 'Tumor Necrosis Factors'

Definition: A family of proteins that were originally identified by their ability to cause NECROSIS of NEOPLASMS. Their necrotic effect on cells is mediated through TUMOR NECROSIS FACTOR RECEPTORS which induce APOPTOSIS.

Registry Number: 0

Descriptor UI: D048069

Alternative terms: Tumor Necrosis Factors; Necrosis Factors, Tumor; TNF Receptor Ligands; Receptor Ligands, TNF; Tumor Necrosis Factor Superfamily Ligands;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D12.644.276.374.750; D12.644.276.972; D12.776.467.374.750; D12.776.467.972; D23.529.374.750; D23.529.972;

History Note: 2005